Bookmarks
Trends of gabapentinoid prescribing associated overdose and mortality in chronic pain patients and the impact of gabapentinoid classification as a controlled drug
Safe People
University of Nottingham
Academic Institute
Roger Knaggs - Chief Investigator - University of NottinghamJoud Alfriah - Corresponding Applicant - University of NottinghamJohn Williams - Collaborator - University of NottinghamSonia Gran - Collaborator - University of Nottingham
Safe Projects
CPRD863
Chronic pain causes substantial suffering and disability worldwide. Several studies have shown that two-fifths of the UK population live with pain that has lasted for three months or longer. The National Institute for Health and Care Excellence (NICE) recommends that clinicians consider several other medicines classes before considering opioids for patients with chronic non-cancer pain. Recent research has highlighted the increase in gabapentinoid (gabapentin and pregabalin) use in pain management.
In the UK, gabapentin was licensed as an adjunct antiepileptic therapy for partial seizures and treating focal seizures in 1993. In 2000, gabapentin gained its approval as an analgesic for managing neuropathic pain and postherpetic neuralgia. Pregabalin was licensed in 2004 for treating neuropathy, postherpetic neuralgia, as an add-on drug to treat resistant partial epilepsy and generalised anxiety disorder.
21/01/2021
Safe Data
HES Admitted Patient Care
ONS Death Registration Data
Patient Level Index of Multiple Deprivation
Safe Setting
Release